Expert Illustrations and Commentaries: Finding the Best Path Forward in PAH Management - A Focus on Prostacyclin Therapy

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

This activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

Credit Available

• Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
• Nurses — 0.75 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward pulmonologists, cardiologists, rheumatologists, primary care physicians, nurse practitioners, physician assistants, and additional health care professionals involved in the care of patients with PAH.

Program Overview

This Expert Illustrations and CommentariesTM is a video-based program in which 2 experts discuss the role of prostacyclin therapy in the management of pulmonary arterial hypertension (PAH). In this activity, the faculty focus on methods to facilitate an accurate and early diagnosis of PAH, as well as best practices in individualizing PAH treatment. Their discussion is enriched with the use of a video animation to illustrate the mechanism of action of prostacyclin therapy in PAH. The use of this animated segment helps make somewhat complicated subject matter more easily understood. This unique format is designed to help clinicians identify best practices in the diagnosis and management of PAH and to improve outcomes for their patients with this disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Determine best practices for identifying patients at risk of PAH
• Review available assessment tools for prompt diagnosis and classification of PAH
• Assess the safety and efficacy of new and emerging therapies for the management of patients with PAH
• Develop individualized treatment plans based on current practice guidelines for optimal management of patients with PAH

Faculty

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 0.75 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Kristin Highland, MD, MSCR

• Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Acceleron Pharma; Boehringer Ingelheim; Gossamer Bio; Reata Pharmaceuticals; United Therapeutics; Viela Bio, Inc.
• Consultant: Actelion Pharmaceuticals US, Inc.; Acceleron Pharma; Boehringer Ingelheim; United Therapeutics
• Speakers’ Bureau: Actelion Pharmaceuticals US, Inc.; Bayer; United Therapeutics; Boehringer Ingelheim

Deborah Jo Levine MD FCCP, has no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

1. Complete the activity (including pre- and post-activity assessments).
2. Answer the evaluation questions.
3. Request credit using the drop-down menu.

You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.